BIOMAT Database Logo BIOMAT Database Logo

Ribozymes as potential anti-HIV-1 therapeutic agents. 1990

N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Division of Research and Development Program, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

Certain RNA molecules, called ribozymes, possess enzymatic, self-cleaving activity. The cleavage reaction is catalytic and no energy source is required. Ribozymes of the "hammerhead" motif were identified in plant RNA pathogens. These ribozymes possess unique secondary (and possibly tertiary) structures critical for their cleavage ability. The present study shows precise cleavage of human immunodeficiency virus type 1 (HIV-1) sequences in a cell-free system by hammerhead ribozymes. In addition to the cell-free studies, human cells stably expressing a hammerhead ribozyme targeted to HIV-1 gag transcripts have been constructed. When these cells were challenged with HIV-1, a substantial reduction in the level of HIV-1 gag RNA relative to that in nonribozyme-expressing cells, was observed. The reduction in gag RNA was reflected in a reduction in antigen p24 levels. These results suggest the feasibility of developing ribozymes as therapeutic agents against human pathogens such as HIV-1.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012335 RNA, Ribosomal The most abundant form of RNA. Together with proteins, it forms the ribosomes, playing a structural role and also a role in ribosomal binding of mRNA and tRNAs. Individual chains are conventionally designated by their sedimentation coefficients. In eukaryotes, four large chains exist, synthesized in the nucleolus and constituting about 50% of the ribosome. (Dorland, 28th ed) Ribosomal RNA,15S RNA,RNA, 15S
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.
January 1992, Advances in experimental medicine and biology,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.
February 1992, AIDS research and human retroviruses,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Ribozymes: use as anti-HIV therapeutic molecules.
January 1993, Antisense research and development,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Ribozymes as human therapeutic agents.
June 1995, Journal of medicinal chemistry,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
1',2'-seco-dideoxynucleosides as potential anti-HIV agents.
January 1989, Journal of medicinal chemistry,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Alkaloids as Potential Anti-HIV Agents.
January 2023, Current HIV research,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
RNA enzymes (ribozymes) as antiviral therapeutic agents.
July 1990, Trends in biotechnology,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
The potential of ribozymes as antiviral agents.
June 1995, Trends in microbiology,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review.
January 2022, Current topics in medicinal chemistry,
N Sarver, and E M Cantin, and P S Chang, and J A Zaia, and P A Ladne, and D A Stephens, and J J Rossi
Anti-HIV ribozymes.
June 1997, Molecular biotechnology,
Copied contents to your clipboard!